Multiply Labs has entered a partnership with AstraZeneca to automate cell therapy manufacturing workflows. The collaboration focuses on applying robotics and software to labor-intensive production steps that currently limit scalability and consistency in personalized cell therapies.
Multiply Labs’ platform uses modular robotic systems to automate cell handling, filling, and finishing processes under sterile conditions. By reducing manual intervention, the system is designed to minimize contamination risk, standardize batch quality, and support parallel processing of patient-specific therapies. The automation approach integrates with existing biomanufacturing infrastructure rather than requiring purpose-built facilities.
The partnership highlights increasing interest in automation as cell therapies move toward broader clinical and commercial use. As demand grows, manufacturers face pressure to reduce costs and variability while maintaining strict regulatory compliance. Robotics-enabled production platforms are emerging as foundational infrastructure for scaling advanced therapies beyond small-batch, manual operations.
Disclaimer: RobotsBeat is an independent media brand owned and operated by NuvexMedia LLC, publishing news, research, and insights on artificial intelligence, emerging technologies, automation, and related industries. NuvexMedia LLC invests in and collaborates with companies across the AI, Robotics, technology, software, and digital innovation sectors. These relationships do not influence RobotsBeat's editorial coverage, and the publication maintains full editorial independence to provide accurate, timely, and objective information. © 2026 NuvexMedia LLC. All rights reserved. This content is for informational purposes only and should not be considered legal, tax, investment, financial, or other professional advice.
